Bernie Romanin

Chief Executive Officer and Director

Dr. Robyn A. Lindley

Chief Scientific Officer and Director

Kevin Hollingsworth

Chief Financial Officer

Inventor and Developer of the TSM Platform.
BSc, MInfoTech, PhD

Dr. Robyn A. Lindley is Science Director, and an Honorary Senior Fellow in the Department of Pathology, Faculty of Medicine, Dentistry and Health Sciences at the University of Melbourne in Australia. Although her first degrees are in physics and informatics, Robyn is an immunogeneticist who has been publishing on the molecular mechanisms of evolution and somatic hypermutation for almost two decades.

Robyn has been credited as a co-discoverer of the first data-driven evidence showing that the immunoglobulin somatic hypermutation process involves an mRNA intermediate, and that the strand-bias mutation signatures generated during somatic hypermutation of immunoglobulin genes, are evident in several cancers. She is the sole discoverer of the specific codon-contexted targeted somatic mutation (TSM) signatures of nucleotide-specific deaminase enzymes that are now heavily implicated in many cancers.

More recently, Robyn has developed methods to identify the inferred deaminase binding domains of enzymes that predict recurrence of cancer. She is turning these foundation discoveries into new genetic tests.

Richard Rendell

CTO & Director

Dr. Nathan Hall

Senior Scientist

Dr. Jared Mamrot